Gonadorelin — compound monograph
Endogenous decapeptide, gonadotropin-releasing hormone. Approved. The Institute assesses 2 outcomes for this compound and grades the strongest at moderate certainty.
§1Identification and status
§1.1Nomenclature
- Preferred name
- Gonadorelin
- Compound class
- Endogenous decapeptide, gonadotropin-releasing hormone
- Assessment series
- Reproductive-axis peptides
- Synonyms and codes
- GnRH · LHRH · luteinising hormone-releasing hormone · gonadorelin (INN)
- Route as evaluated
- Intravenous or subcutaneous for the approved diagnostic use
§1.2Chemistry
Chemical identifiers are reproduced where they are public. Where a structure has not been published the monograph records not disclosed rather than constructing one.[1]
- CAS registry number
- 33515-09-2
- Molecular formula
- C55H75N17O13
- Average mass
- 1182.29
- Monoisotopic mass
- 1181.58
- ATC classification
- H01CA01 · V04CM01
§1.3Sequence and structural notes
The native mammalian gonadotropin-releasing hormone decapeptide. The N-terminal pyroglutamate and the C-terminal Gly-NH₂ are both essential for activity. It is included in this series because it holds marketing authorisations for diagnostic use and because it is widely supplied through research channels for purposes unrelated to those authorisations.
§1.4Assessment status
The Institute assesses Gonadorelin across 2 indications and grades the strongest of them at moderate certainty. Holds a marketing authorisation for at least one indication in at least one jurisdiction.
Table 1. Assessed outcomes for Gonadorelin, ordered by certainty. Each row links to the per-indication evidence extract.
| Indication | Effect as recorded | Certainty | Trials |
|---|---|---|---|
| Growth hormone deficiency and growth-hormone secretagogue pharmacology | A luteinising hormone rise after gonadorelin distinguishes pituitary from hypothalamic causes of hypogonadotropic hypogonadism | Moderate | 1 |
| Polycystic ovary syndrome | Pulsatile administration by pump induces ovulation in hypothalamic amenorrhoea with reported ovulation rates above 80 % per cycle in selected patients | Moderate | 1 |
| Effects are reproduced as the contributing trials reported them. Where a confidence interval is held it appears on the per-indication extract rather than in this summary table. | |||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.